Drugs / [89]Zr-DFO-VRC-HIVMAB060-00-AB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03729752 | Nov 2018 → Oct 2026 expected | HIV infectious disease | University of California, San Francisco | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [89]Zr-DFO-VRC-HIVMAB060-00-AB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03729752 ↗ |
| Known as | 89Zr-DFO-VRC01 | “Four serial PET-MR scans over 120 hours following a single, bolus injection of \[89\]Zr-DFO-VRC-HIVMAB060-00-AB (89Zr-DFO-VRC01).” NCT03729752 ↗ |
| Modality | Monoclonal antibody | “Radiolabeled monoclonal antibody that targets the envelope protein of HIV-1.” NCT03729752 ↗ |